Advertisement

Topics

Latest "Global Dairy Platform" News Stories - Page: 20

22:53 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "Global Dairy Platform" found in our extensive news archives from over 250 global news sources.

More Information about Global Dairy Platform on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Global Dairy Platform for you to read. Along with our medical data and news we also list Global Dairy Platform Clinical Trials, which are updated daily. BioPortfolio also has a large database of Global Dairy Platform Companies for you to search.

Showing "Global Dairy Platform" News Articles 476–500 of 20,000+

Thursday 6th December 2018

Mylan launches generic Prevacid SoluTab DR ODT in US markets

Global pharmaceutical company Mylan NV announced the US launch of lansoprazole delayed─release (DR) orally disintegrating tablets (ODT), 15 mg and 30 mg, a generic version of Takeda's Prevacid SoluTab DR ODT.


Trichuriasis Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2125

Trichuriasis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Trichuriasis Global Clinical Trials Review, H2, 2018" provides an overview of Trichuriasis clinical trials scenario. This report provides top line data relating to the clinical trials on Trichuriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted acr...

Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada. The milestone payment is associated with the companies’ collaboration for a non-complement cardiovascular target with a large market opportunity. Initiated in 201...


Global Pharma Guidance Tracker – November 2018

Stay up to date on regulatory guidelines from around the world, with the Pink Sheet's Guidance Tracker. The complete Global...   

Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting

Primary endpoint of non-inferiority in the Duration of Severe Neutropenia (DSN) between ROLONTIS and pegfilgrastim was met No statistically significant differences in adverse event rates between treatment groups RECOVER is the second ROLONTIS Phase 3 study to meet the primary efficacy endpoint of non-inferiority...

Sproutly Announces Hiring New President from Anheuser-Busch InBev and Kimberley Clark

NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly" or the “Company”) is pleased to announce the hiring of Bryan Semkuley to the senior leadership team as President of Sproutly to accelerate the Company’s strategic objectives of becoming a leading cannabis f...

Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day

− In 2019, Alnylam Will Continue ONPATTRO™ Global Launch and Advance Late-Stage Pipeline of Wholly Owned and Partnered Programs with: Five Phase 3 Programs; Three Phase 3 Program Readouts; and Two New Drug Application (NDA) Filings – − Initiates Rolling Submission of Givosiran NDA to U.S. Food and Drug Administration (FDA) – ...

Ablexis Announces Licensing Agreement with Allogene Therapeutics

Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse platform Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Al

Corindus’ Technology Successfully Used in World’s First-in-Human Telerobotic Coronary Intervention

CorPath® telerobotic interventional platform has the potential to deliver timely, specialized cardiovascular treatment to remote, underserved patient populations across the globe. KEY TAKEAWAYS Corindus’ telerobotic coronary interventional platform has the potential to: Dramatically improve patient access for b...

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 29062018] Prices from USD $2125

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollmen...

Queen Silvia of Sweden becomes ADI Ambassador

06 December 2018 – Her Majesty Queen Silvia of Sweden has become an Honorary  Ambassador of Alzheimer’s Disease International (ADI), in recognition of her  personal commitment to work surrounding elderly and end of life care, and specifically dementia. Queen Silvia has a long-standing association with, and support of dementia, in 1996  havi...

Edison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)

Edison Investment Research Limited 06-Dec-2018 / 10:35 GMT/BST London, UK, 6 December 2018 Edison issues update on e-Therapeutics (ETX) e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson's disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX...

e-Therapeutics (ETX) - Releasing hidden value

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson’s disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has...

Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer

30-year Industry Veteran Will Lead Knopp’s Global Commercialization, Business Development Functions as Company Advances Lead Asset into Late Stage Clinical Development Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet ne...

Takeda shareholders approve $62bn Shire acquisition

Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc. The deal is set to see Asia’s largest pharma firm become a major global player, as the acquisition is set to propel the Osaka-based company into the top 10 biggest pharmaceutical firms worldwide. The approval comes after a long and convoluted process through whi...

SmallCell Lung Cancer Global Clinical Trials Review, H2, 2018 [Report Updated: 31072018] Prices from USD $2125

SmallCell Lung Cancer Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, SmallCell Lung Cancer Global Clinical Trials Review, H2, 2018" provides an overview of SmallCell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on SmallCell Lung Cancer. Report includes an overview of trial numbers and their average enrol...

Seasonal Influenza: Competitive Landscape to 2026 [Report Updated: 08112018] Prices from USD $2971

Seasonal Influenza: Competitive Landscape to 2026SummaryInfluenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. The influenza A H1N1 and H3N2, and influenza B strains are those responsible for seasonal influenza infections. The symptoms of influenza are similar to those of the common cold, though t...

Overdiagnosis and industry influence: how cow’s milk protein allergy is extending the reach of infant formula manufacturers

Allergy to cow’s milk protein may be acting as a Trojan horse for the $50bn (£40bn; €44bn) global formula industry to forge relationships with healthcare professionals in the UK and around the...

Evotec and Immuneering to Collaborate on Artificial Intelligence Driven Ligand Identification for rare Hereditary Diseases

Evotec AG today announced that it has entered into a research collaboration with Immuneering Corporation, a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases. The research collaboration brings together Evotec's leading induced pluripotent stem cell ("iPSC") platform and broad drug discovery capabilities with Immuneering's uniqu...

New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

BD, a leading global medical technology company, has announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix™ CPO detect test, which will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs). The test may help hospitals contain the spread of antimicrobial resistance (AMR) by shortening the time it takes to detect ...

Agtech players innovate to feed a growing population

Demand for more efficient global food production as the population grows is fueling development of new agricultural technolog -More- 

Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2125

Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Tumor Lysis Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Tumor Lysis Syndrome. Report includes an overview of trial numbers and their average enrollmen...

Merck KGaA, Cyclica in AI Screening Platform Pact

Augmented platform is being used to uncover novel targets that are modeled to interact with a small molecule

Tenosynovitis Global Clinical Trials Review, H2, 2018 [Report Updated: 31082018] Prices from USD $2125

Tenosynovitis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Tenosynovitis Global Clinical Trials Review, H2, 2018" provides an overview of Tenosynovitis clinical trials scenario. This report provides top line data relating to the clinical trials on Tenosynovitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted...

Top General Dentist In Woodland Hills Dr. Kaveh Kanani Unveils an Innovative and Affordable Method To Insert Dental Implants

Dr. Kanani from Kanani Dental Group explains why his method will greatly benefit those who suffer from tooth loss. Patience can now benefit from the annual promotion of $699.00 painless, drill-less and flap-less dental implants. LOS ANGELES (PRWEB) December 06, 2018 Dr. Kaveh Kanani D.D.S. is the head of Kanani Dental Group, the most popular family dentistry clinic in Woodland Hills. This well es...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks